Contributions
Abstract: P802
Type: Poster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Multiple sclerosis (MS) is a degenerative disease that results in impairments in multiple domains including cognition. Fampridine has been approved to improve walking in persons with MS (PwMS). It is plausible that Fampridine could improve cognition through the same mechanisms. We aim to examine effects of Fampridine treatment on cognitive function in two years period.
The patients included in this multi-centre, examiner-blinded, and prospective study were the adults with MS who initiated fampridine treatment at the MS clinic of Dokuz Eylül University Hospital. They were followed up at three centres in Turkey. Patients with Expanded Disability Status Scale (EDSS) scores between 4 and 7 enrolled in the study. To maintain treatment blinding, we used the two-physician principle: a treating neurologist was responsible for overall care of the patient; and an evaluating neurologist assessed patients at scheduled visits and performed cognitive tests, but was not otherwise involved in patient care. Neurological evaluations and cognitive tests were performed at baseline, at the end of the third month, sixth month and then every six month for 2 years. Age, sex and education-matched healthy control people were also evaluated cognitively at the same scheduled visits. For cognitive evaluation The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery, which included the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT-2) and the Brief Visuospatial Memory Test-Revised (BVMT-R) used.
A total of 148 patient (106 female, mean age: 43.4±9.1) and 79 healthy control (51 female, mean age: 41.8±7.5) included in the study. SDMT score improved at month 3 vs baseline (38.1 vs. 40.7, p= 0.007. BVMTR score also improved at month 3 (18.3 vs. 21.9, p=0.008). CVLT2 improved from 40.4 to 42.1, p=0.031). 59 patients (39.9%) were found to be cognitively impaired at study entry on the basis of SDMT under -2 SD. At follow-up 45 patients were cognitively impaired (p=0.008). Number of cognitively impaired patients decreased from 61 to 43 on the basis of CVLT, and 64 to 51 on the basis of BVMTR at month 3. Patients were stable at month 6, month 12, month 18, and month 24. There was no difference between baseline and 24th month in terms of cognitive functions in healthy controls.
The results of this study have indicated that fampridine treatment could improve cognitive functions and improvement could be stable up to two years in PwMS.
Disclosure:
Serkan Ozakbas: nothing to disclose
Pinar Yigit: nothing to disclose
Bilge Piri Cinar: nothing to disclose
Gorkem Kosehasanogullari: nothing to disclose
Abstract: P802
Type: Poster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Multiple sclerosis (MS) is a degenerative disease that results in impairments in multiple domains including cognition. Fampridine has been approved to improve walking in persons with MS (PwMS). It is plausible that Fampridine could improve cognition through the same mechanisms. We aim to examine effects of Fampridine treatment on cognitive function in two years period.
The patients included in this multi-centre, examiner-blinded, and prospective study were the adults with MS who initiated fampridine treatment at the MS clinic of Dokuz Eylül University Hospital. They were followed up at three centres in Turkey. Patients with Expanded Disability Status Scale (EDSS) scores between 4 and 7 enrolled in the study. To maintain treatment blinding, we used the two-physician principle: a treating neurologist was responsible for overall care of the patient; and an evaluating neurologist assessed patients at scheduled visits and performed cognitive tests, but was not otherwise involved in patient care. Neurological evaluations and cognitive tests were performed at baseline, at the end of the third month, sixth month and then every six month for 2 years. Age, sex and education-matched healthy control people were also evaluated cognitively at the same scheduled visits. For cognitive evaluation The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery, which included the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT-2) and the Brief Visuospatial Memory Test-Revised (BVMT-R) used.
A total of 148 patient (106 female, mean age: 43.4±9.1) and 79 healthy control (51 female, mean age: 41.8±7.5) included in the study. SDMT score improved at month 3 vs baseline (38.1 vs. 40.7, p= 0.007. BVMTR score also improved at month 3 (18.3 vs. 21.9, p=0.008). CVLT2 improved from 40.4 to 42.1, p=0.031). 59 patients (39.9%) were found to be cognitively impaired at study entry on the basis of SDMT under -2 SD. At follow-up 45 patients were cognitively impaired (p=0.008). Number of cognitively impaired patients decreased from 61 to 43 on the basis of CVLT, and 64 to 51 on the basis of BVMTR at month 3. Patients were stable at month 6, month 12, month 18, and month 24. There was no difference between baseline and 24th month in terms of cognitive functions in healthy controls.
The results of this study have indicated that fampridine treatment could improve cognitive functions and improvement could be stable up to two years in PwMS.
Disclosure:
Serkan Ozakbas: nothing to disclose
Pinar Yigit: nothing to disclose
Bilge Piri Cinar: nothing to disclose
Gorkem Kosehasanogullari: nothing to disclose